An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared ...

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...

The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes patients.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications ...

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...

A clinical trial found that weekly doses of semaglutide – a medication typically prescribed to Type 2 diabetes patients – ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Research out today is the latest to suggest that semaglutide can significantly lower people's risk of dementia.

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar ...